In vitro receptor binding assays measure how tightly, specifically, and saturably sermorelin engages the GHRH receptor across graded concentrations. Reported values place affinity in the low-nanomolar range, with competitive displacement in pituitary preparations at similar order. Saturation curves that plateau and fit a single-site model support high-affinity binding to one receptor class, and association and dissociation kinetics describe how long occupancy persists once binding begins. What the data does not establish is response, since occupancy and signaling are separate questions.
Key Takeaways
- Sermorelin is the GHRH(1, 29)-NH2 fragment and binds the GHRH receptor on somatotroph cells with reported low-nanomolar affinity.
- Saturation binding yields KD; competitive binding against a labeled reference ligand yields IC50, which converts to Ki given the reference ligand’s own affinity.
- A curve that plateaus and fits a single-site model supports one high-affinity receptor class rather than heterogeneous binding.
- Association and dissociation kinetics determine residence time, which shapes signaling duration independently of affinity.
- Binding affinity does not predict functional response. Coupling efficiency, receptor reserve, internalization, and desensitization all intervene.
What is sermorelin and how does it bind
Sermorelin is the 29-residue N-terminal fragment of human GHRH, supplied as GHRH(1, 29)-NH2. Native GHRH is 44 residues, and the C-terminal region beyond position 29 is dispensable for receptor engagement. The fragment retains the determinants required for binding, and the C-terminal amidation preserves activity comparable to the parent hormone.
Binding follows the pattern expected of a peptide agonist at a class B GPCR. The peptide contacts the receptor, promotes an active conformation, and the receptor couples to Gs, raising intracellular cAMP. The binding event and the signaling event are linked but distinct, which is the distinction the rest of this page turns on.
Two properties are worth separating from the start:
- Affinity describes how tightly the peptide binds at equilibrium. It sets the concentration range over which receptors become occupied.
- Kinetics describe how quickly binding forms and how long it lasts. Two ligands with identical affinity can have very different residence times, and residence time is often the better predictor of signaling duration.
How do you measure receptor affinity in vitro
Affinity is measured by exposing receptor-bearing membrane or whole-cell preparations to graded ligand concentrations and quantifying bound versus free. The essential operation is not the binding itself but the subtraction.
Saturation binding uses a labeled ligand across a concentration series to yield KD and Bmax. Total binding is measured directly. Nonspecific binding is measured in parallel wells containing a large excess of unlabeled competitor, which occupies the specific sites and leaves only what sticks to plastic, lipid, and filter. Specific binding is the difference. KD comes from fitting that difference, never from the total.
Competitive binding holds a labeled reference ligand at fixed concentration and displaces it with unlabeled sermorelin across a series, yielding IC50. IC50 is assay-dependent: it shifts with the concentration and affinity of the reference ligand used. The Cheng-Prusoff relationship converts IC50 to Ki, which is the comparable quantity. An IC50 reported without the reference ligand and its concentration cannot be compared against an IC50 from another lab.
Kinetic assays track association and dissociation separately to give kon, koff, and residence time. KD equals koff divided by kon, so kinetics and affinity are not independent measurements but two views of the same interaction.
The quality checks that matter:
- Does the curve plateau? If it does not, the concentration range did not reach saturation and KD is an extrapolation.
- Does a single-site model fit? A two-site fit that improves substantially suggests receptor heterogeneity, a second binding population, or an artifact.
- Is nonspecific binding a small fraction of total? When nonspecific dominates, the specific signal is a small difference between two large numbers, and its error bars are correspondingly large.
- Is ligand depletion negligible? At high receptor concentration and low ligand concentration, binding removes enough free ligand to bias the fit.
What receptor does sermorelin engage
Sermorelin engages the growth hormone-releasing hormone receptor, GHRH-R, a class B GPCR expressed on anterior pituitary somatotrophs.
Reported affinity sits in the low-nanomolar range, with competitive displacement in pituitary preparations at comparable order. Binding is saturable and consistent with a single high-affinity receptor class rather than multiple populations. Functional endpoints downstream, cAMP accumulation and GH release from pituitary cell preparations, also fall in the nanomolar range.
The kinetic pattern reported for sermorelin is fast association and comparatively slow dissociation, which supports occupancy persisting after the free concentration falls. That pattern is the more informative part of the kinetic story, because it is what distinguishes a ligand that engages and leaves from one that engages and stays.
Specific kon, koff, and KD values vary between preparations, labeling strategies, and reference ligands, which is why a single figure quoted without its assay conditions carries less information than it appears to.
How does sermorelin affinity compare to other analogs
Sermorelin’s affinity is generally reported as close to native GHRH(1, 44), which is the expected result given that it retains the receptor-interacting region and drops a dispensable one. Comparisons against other analogs require more care than they usually receive.
| Analog | Structural basis | What binding data can and cannot say |
|---|---|---|
| GHRH(1, 44) | Native hormone | Reference point for intrinsic affinity |
| Sermorelin (1, 29) | Truncated to the active core | Affinity comparable to native; truncation does not cost receptor engagement |
| Substituted analogs | Residue changes for protease resistance | Substitutions can shift affinity in either direction; measured, not assumed |
| Albumin-binding analogs | Conjugation extends circulating exposure | In vitro affinity says nothing about the exposure mechanism, which is a distribution property |
The last row is the one most often misread. A conjugation strategy that extends half-life operates on clearance, not on receptor binding. Comparing a conjugated analog’s in vitro KD against sermorelin’s tells you about the modified peptide’s receptor interaction and nothing at all about the property the modification was designed to change.
Similarly, a leftward shift in a competition curve indicates tighter apparent engagement under those specific conditions. Whether it reflects genuine affinity difference or differing assay setup requires the reference ligand, its concentration, and the preparation to be stated.
What affinity does not tell you
This is where binding data is most often over-read, and the gap is structural rather than a matter of care.
Affinity is not efficacy. A ligand can occupy a receptor with high affinity and produce little or no response. Antagonists demonstrate this in the extreme case: maximal occupancy, zero signal. Occupancy is necessary for agonism and does not constitute it.
Occupancy and response curves rarely align. In systems with receptor reserve, a maximal functional response can occur while a small fraction of receptors are occupied, which places the functional EC50 well left of the binding KD. The size of that gap is a property of the cell system, not the ligand, so it changes between preparations.
Coupling efficiency intervenes. The path from active conformation to measured cAMP runs through G protein availability, effector density, and phosphodiesterase activity. Differences in any of these shift the functional curve without touching binding.
The receptor does not hold still. Internalization removes receptors from the surface during sustained exposure. Desensitization reduces coupling. Tachyphylaxis at the GHRH receptor is a documented feature of sustained stimulation, and an equilibrium binding measurement captures none of it.
The practical statement is narrow. Binding data identifies the concentration range in which receptor engagement occurs, and it establishes that engagement is specific and saturable. Everything about what happens afterward comes from functional assays run separately.
How do binding and functional data fit together
Binding and functional assays answer sequential questions, and the value is in the sequence rather than in either alone.
- Binding establishes the target. Saturable, single-site, displaceable binding says the interaction is with a defined receptor population rather than a surface.
- Kinetics establish the duration. Fast on and slow off means occupancy outlasts exposure, which is a different claim from tight binding at equilibrium.
- cAMP establishes coupling. The receptor engaged and the Gs pathway responded. This is the first evidence of agonism rather than occupancy.
- GH release establishes the integrated response. The signal propagated through to secretion in a cell that has the machinery for it.
Convergence across all four, in the same preparation, is what supports a claim about potency. A KD alone supports a claim about binding.
Conclusion
Sermorelin binds the GHRH receptor with reported low-nanomolar affinity, saturably, at a single site, with fast association and slower dissociation. That is a clean result and a narrow one. It says the truncated GHRH(1, 29) fragment retains the receptor-interacting region of the parent hormone, which is what the structure predicts and what the data confirms.
The interpretive discipline is in what follows. Affinity sets the concentration range for occupancy. It does not set the response, because receptor reserve, coupling efficiency, internalization, and desensitization all sit between binding and output, and none of them appear in a saturation curve. A ligand with excellent affinity and poor coupling produces excellent binding data and little signal.
The habits that make binding data usable are unglamorous. Report the reference ligand and its concentration alongside any IC50, since the number is meaningless without them. Confirm the curve plateaued before quoting a KD from it. Check that nonspecific binding is a small fraction of total rather than most of it. And treat the functional assay as the thing that establishes potency, with binding as the thing that establishes where to look for it.
Shop Research Peptides at Holas Today
If you are looking for research peptides that are properly handled, securely packaged, and shipped with care, Holas has you covered. We provide laboratory-grade peptides with third-party tested purity, reliable packaging standards, and fast shipping to support your research needs. Browse our full catalog or contact us to source the right peptides for your protocol.
Frequently Asked Questions
What is sermorelin’s affinity for the GHRH receptor?
Reported values place it in the low-nanomolar range, generally comparable to native GHRH(1, 44). Specific figures vary with the preparation, labeling strategy, and reference ligand used, so a value quoted without its assay conditions carries limited information.
What is the difference between KD and IC50?
KD comes from saturation binding and describes affinity directly. IC50 comes from competitive displacement and is assay-dependent, shifting with the concentration and affinity of the reference ligand used. The Cheng-Prusoff relationship converts IC50 to Ki, which is the quantity comparable across studies.
Why is nonspecific binding measured separately?
Total binding includes ligand stuck to plastic, lipid, and filter alongside genuine receptor occupancy. Nonspecific binding is measured in parallel wells containing excess unlabeled competitor, and specific binding is the difference. KD is fitted to that difference. Fitting the total instead overstates binding and distorts the estimate.
Does high affinity mean high potency?
No. A ligand can occupy a receptor tightly and produce little response, which is what antagonists do. Occupancy is necessary for agonism but does not constitute it. Potency depends additionally on coupling efficiency and on the cell system’s receptor reserve.
Why do occupancy and response curves not align?
In systems with receptor reserve, a maximal functional response can occur while only a fraction of receptors are occupied, which places the functional EC50 left of the binding KD. The size of that gap is a property of the cell preparation rather than the ligand, so it changes between systems.
What does residence time add beyond affinity?
Two ligands with identical KD can have very different association and dissociation rates, since KD equals koff divided by kon. Fast association with slow dissociation means occupancy persists after free concentration falls, which often predicts signaling duration better than equilibrium affinity does.
Why does binding data not predict in vivo response?
Equilibrium binding measures a static interaction. Sustained receptor stimulation triggers internalization, which removes receptors from the surface, and desensitization, which reduces coupling. Tachyphylaxis at the GHRH receptor is a documented feature of sustained exposure and appears nowhere in a saturation curve.
